Special Drug Use Investigation of Xarelto for VTE
Phase of Trial: Phase IV
Latest Information Update: 24 May 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- Acronyms JPMS-XAR-VTE
- Sponsors Bayer
- 07 Jun 2017 Biomarkers information updated
- 29 Aug 2016 Planned End Date changed from 1 Mar 2019 to 1 Jan 2020.
- 17 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.